Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
Dr. Lukasz Chrzanowski,
It is now well recognized that despite major achievements in antineoplastic therapy, there is increasing medical concern about cardiovascular complications in this patient population. Consequently, a new discipline has been referred to as cardio-oncology, with the intention of reducing the risk of heart and vessel directed toxicity without a concomitant unfavourable impact on the beneficial effects associated with treatment against malignancies.
The session included four presentations. First, Doctor Juan Carlos Plana from Cleveland (US) provided interesting insights into cardiovascular side effects of cancer drugs.Then, Professor Ana Maria G. Almeida from Lisbon (Portugal) questioned whether ejection fraction, as a parameter, is enough to monitor cancer therapy.
In the third presentation, Doctor Evgeny Shkolnik from Moscow (Russia) talked about a potential added value of deformation imaging for detection and monitoring of cardiotoxicity.Finally, Doctor Thomas H Marwick from Hobart (Australia) pointed out the need for, and difficulties in developing standardised protocols that would integrate cardiovascular imaging into the management of patients in the field of oncology. Since there is substantial variation in malignant disorders, treatment protocols and mechanisms of cardiovascular complications, further studies are needed before more definite conclusions can be introduced.
Left ventricular systolic function remains a very important element in the assessment of cardiotoxicity, but prediction of its impairment or potential for developing reversible abnormalities remains a challenge. On the other hand, prevention using treatment with some well known cardiovascular therapeutic agents including angiotensin converting enzyme inhibitors/ angiotensin receptor blockers, beta-blockers and statins, is promising due to their protective effect.
Why do we need cardiac imaging in cancer therapy?
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved